Menu
Search
|

Menu

Close
X

Karyopharm Therapeutics Inc KPTI.OQ (NASDAQ Stock Exchange Global Select Market)

14.98 USD
+0.21 (+1.42%)
As of Feb 16
chart
Previous Close 14.77
Open 14.84
Volume 107,285
3m Avg Volume 59,870
Today’s High 15.61
Today’s Low 14.78
52 Week High 15.61
52 Week Low 7.54
Shares Outstanding (mil) 47.18
Market Capitalization (mil) 706.77
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.73 Mean rating from 11 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-2.005
FY16
-2.934
FY15
-3.317
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.43
Price to Sales (TTM)
vs sector
5,989.56
8.57
Price to Book (MRQ)
vs sector
5.00
5.14
Price to Cash Flow (TTM)
vs sector
--
25.75
Total Debt to Equity (MRQ)
vs sector
0.00
15.12
LT Debt to Equity (MRQ)
vs sector
0.00
11.85
Return on Investment (TTM)
vs sector
-75.09
13.54
Return on Equity (TTM)
vs sector
-75.87
14.80

EXECUTIVE LEADERSHIP

Sharon Shacham
President, Co-Founder, Chief Scientific Officer, Director, Since 2013
Salary: $415,000.00
Bonus: $166,000.00
Michael Kauffman
Co-Founder, Chief Executive Officer and Director, Since
Salary: $515,000.00
Bonus: $247,200.00
Michael Falvey
Chief Financial Officer, Executive Vice President, Treasurer, Principal Financial Officer, Principal Accounting Officer, Since 2017
Salary: --
Bonus: --
Christopher Primiano
Senior Vice President, General Counsel, Secretary, Since 2015
Salary: --
Bonus: --
Michael Todisco
Vice President - Finance, Assistant Treasurer, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

85 Wells Ave
NEWTON CENTER   MA   02459-3298

Phone: +1617.6580600

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1. The Company's lead drug candidate, selinexor (KPT-330), is an orally administered agent for the treatment of cancer indications with unmet clinical need, mainly hematologic malignancies. It is also engaged in the clinical development of selinexor in various solid tumor indications. Oral selinexor is being evaluated in multiple later-phase clinical trials in patients with relapsed and/or refractory hematological and solid tumor malignancies. Its lead drug candidate, oral selinexor (KPT-330), as well as verdinexor (KPT-335), KPT-8602 and KPT-9274 are in clinical development.

SPONSORED STORIES